Healthcare / Diagnostics & ResearchNasdaqGM
$18.30
+0.21 (+1.16%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-19.3M · quality 53.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$520M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-5.4%
↓Gross Margin
40.6%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
+65.3%
FCF CAGR
—
FCF margin
-38.5%
FCF / Net income
2.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $322.7M · net income $-60.5M · FCF $-124.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | $322.7M | $322.7M | $283.5M | $289.2M | $619.0M | $992.6M | $421.7M | $32.5M | $21.4M | $18.7M | $18.3M | $9.6M | $1.3M |
| Net Income | $-60.5M | $-60.5M | $-42.7M | $-167.8M | $143.4M | $507.4M | $214.3M | $-411000.00 | $-5.6M | $-2.5M | $-5.3M | $-8.3M | $-4.3M |
| EBITDA | $-45.8M | $-45.8M | $-49.0M | $-147.5M | $217.7M | $687.0M | $293.1M | $1.7M | — | $-1.8M | $2.1M | $-4.4M | $-794000.00 |
| EPS | -1.97 | -1.97 | -1.41 | -5.63 | 4.63 | — | — | — | — | — | — | — | — |
| Gross Margin | 40.6% | 40.6% | 37.8% | 36.1% | 59.3% | 78.3% | 78.7% | 56.6% | 49.9% | 54.3% | 63.2% | 47.1% | 26.8% |
| Operating Margin | -28.2% | -28.2% | -26.1% | -26.0% | 29.3% | 68.1% | 68.8% | -1.3% | -23.7% | -18.6% | 5.0% | -52.3% | -77.5% |
| Net Margin | -18.8% | -18.8% | -15.1% | -58.0% | 23.2% | 51.1% | 50.8% | -1.3% | -26.3% | -13.4% | -29.3% | -86.8% | -335.1% |
| Balance Sheet | |||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | — | — | — | — | — | — | — | — |
| Current Ratio | 5.32 | 5.32 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-124.2M | $-124.2M | $-19.3M | $4.8M | $234.7M | $514.8M | $105.5M | $4.3M | $-3.0M | $-1.6M | $617000.00 | $-3.1M | $-5.1M |
| Returns | |||||||||||||
| ROE | -5.4% | -5.4% | -3.8% | -14.8% | 11.3% | 43.8% | 37.6% | -0.5% | -11.0% | -4.6% | -9.8% | -161.6% | -254.3% |
| Valuation | |||||||||||||
| P/E | — | — | — | — | 6.39 | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | — | — | 4.02 | — | — | — | — | — | — | — | — |
| P/B | 0.51 | 0.51 | 0.50 | 0.74 | 0.72 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | 13.8% | 13.8% | -2.0% | -53.3% | — | 135.4% | 1196.5% | 52.3% | 14.0% | 2.5% | 90.9% | 649.3% | — |
| EPS Growth | -39.7% | -39.7% | 75.0% | -221.6% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.41 → -1.97
Residual
-11.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.